Home Featured Page 212

Featured

Latest

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Filament Health and Cybin Therapeutics Announce Licensing Agreement

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule...

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary...

PharmaDrug Announces Resignation of Director

PT284 – Jonathan Sabbagh – Ketamine-Assisted Psychotherapy and Collaborative Care

Mydecine to Launch Special Access Support and Supply Program in Canada...

Wesana Health Provides Strategic and Operational Updates

MYND Life Sciences Announces Collaborative Research Agreement with the University of...

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for...

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Filament Health and Cybin Therapeutics Announce Licensing Agreement

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule...

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary...

PharmaDrug Announces Resignation of Director

PT284 – Jonathan Sabbagh – Ketamine-Assisted Psychotherapy and Collaborative Care

Mydecine to Launch Special Access Support and Supply Program in Canada...

Wesana Health Provides Strategic and Operational Updates

MYND Life Sciences Announces Collaborative Research Agreement with the University of...

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for...

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY